Equillium, Inc. (NASDAQ:EQ) Sees Significant Decline in Short Interest

by · The Cerbat Gem

Equillium, Inc. (NASDAQ:EQ – Get Free Report) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 363,900 shares, a decline of 45.9% from the February 13th total of 672,300 shares. Based on an average trading volume of 770,000 shares, the short-interest ratio is currently 0.5 days. Currently, 2.1% of the company’s shares are sold short.

Hedge Funds Weigh In On Equillium

An institutional investor recently raised its position in Equillium stock. DCF Advisers LLC increased its stake in shares of Equillium, Inc. (NASDAQ:EQ – Free Report) by 91.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,947 shares of the company’s stock after buying an additional 29,985 shares during the quarter. DCF Advisers LLC owned about 0.18% of Equillium worth $47,000 as of its most recent SEC filing. Institutional investors and hedge funds own 27.05% of the company’s stock.

Equillium Price Performance

NASDAQ EQ traded down $0.03 on Friday, hitting $0.75. The stock had a trading volume of 111,892 shares, compared to its average volume of 365,234. The business’s fifty day moving average price is $0.76 and its 200 day moving average price is $0.81. Equillium has a 52-week low of $0.49 and a 52-week high of $2.99. The stock has a market cap of $26.75 million, a price-to-earnings ratio of -5.39 and a beta of 1.87.

Equillium Company Profile

(Get Free Report)

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.

Featured Stories